Table 1.
Baseline patient, tumor and treatment characteristic
| Factor | VCF Cohort (N=34) | No VCF Cohort (N=153) | Percent VCF Based on Total Cohort (N=187) |
| Spine level: | |||
| Cervical | 3 | 12 | 3/15 (20%) |
| Thoracic | 15 | 74 | 15/89 (16.85%) |
| Lumbar | 16 | 50 | 16/66 (24.24%) |
| Sacrum | 0 | 17 | 0/17 (0%) |
| Paraspinal/Epidural Disease: | |||
| Present | 26 | 96 | 26/122 (21.31%) |
| Absent | 8 | 57 | 8/65 (12.31%) |
| On targeted systemic therapies | 22 | 122 | 22/144 (15.28%) |
| On bisphosphonate therapy | 11 | 44 | 11/55 (20%) |
| Prior Radiation: | |||
| Present | 3 | 31 | 3/34 (8.82%) |
| Absent | 31 | 122 | 31/153 (20.26%) |
| Mean Age (range) in years | 59.38 | 60.39 | 60.20 (33-87.67) |
| (33-87.67) | (41-81) | ||
| Segment | |||
| Single | 28 | 66 | 28/94 (29.79%) |
| Multiple within a single field | 6 | 87 | 6/93 (6.45%) |
| Total Dose/Fraction: | |||
| 10-18Gy/1frx | 14 | 87 | 14/101 (13.86%) |
| 20-24Gy/1frx | 14 | 26 | 14/40 (35%) |
| 18-24 Gy/2frx | 2 | 16 | 2/20 (10%) |
| 18-30Gy/3frx | 2 | 1 | 2/18 (11.11%) |
| 25-30Gy/4frx | 1 | 5 | 1/2 (50%) |
| 25-30Gy/5frx | 1 | 1/6 (20%) | |
| Dose/Fraction: | |||
| <=19Gy | 20 | 127 | 20/147 (13.61%) |
| 20-23 Gy | 4 | 13 | 4/17 (23.53%) |
| ≥24 Gy | 10 | 13 | 10/23 (43.48%) |
| Median Follow-Up to Fracture (range) in months | 2.35 | 10.22 | 8.02 (0.03-75.99) |
| (0.03-43.01) | (1.05-75.99) |